Vical Incorporated (NASDAQ:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the Company will present a poster summarizing results from preclinical studies of its antifungal compound, VL-2397 (formerly known as ASP2397), at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy joint meeting in San Diego, California. The poster, titled “Pharmacokinetic and Pharmacodynamic Characterization of ASP2397, a Novel Potent Antifungal Agent with Activity against Invasive Pulmonary Aspergillosis,” will be presented during the “New Anti-Fungal Agents” poster session on September 19, 2015 from 11:00am to 1:00pm PT.
VL-2397 is part of a potential new class of antifungal compounds for the treatment of systemic fungal infections. Systemic fungal infections are major causes of morbidity and mortality in immunocompromised patients, such as transplant recipients, in patients undergoing chemotherapy and in patients in the ICU. In preclinical studies to date, VL-2397 has demonstrated faster fungicidal activity than marketed drugs and activity against azole-resistant fungal pathogens. VL-2397 was initially developed by Astellas Pharma Inc. (TOKYO: 4503). In March 2015, Astellas granted Vical an exclusive worldwide license to develop and commercialize VL-2397. The Food and Drug Administration has granted a qualified infectious disease product (QIDP) designation to VL-2397 for the treatment of invasive aspergillosis. Vical intends to file an investigational new drug application and initiate a Phase 1 clinical trial for VL-2397 in the first half of 2016. (Original Source)
Shares of Vical closed yesterday at $0.58. VICL has a 1-year high of $1.55 and a 1-year low of $0.53. The stock’s 50-day moving average is $0.61 and its 200-day moving average is $0.85.
On the ratings front, Vical has been the subject of a number of recent research reports. In a report issued on June 23, Roth Capital analyst Debjit Chattopadhyay downgraded VICL to Hold, with a price target of $1.65, which represents a potential upside of 184.5% from where the stock is currently trading. Separately, on the same day, H.C. Wainwright’s Mark Breidenbach reiterated a Buy rating on the stock and has a price target of $2.50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Debjit Chattopadhyay and Mark Breidenbach have a total average return of 25.1% and -12.6% respectively. Chattopadhyay has a success rate of 62.3% and is ranked #15 out of 3757 analysts, while Breidenbach has a success rate of 33.3% and is ranked #3333.
Vical Inc is engaged in researching and developing biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.